Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts By Watertime - July 21, 2026 2 Post Content RELATED ARTICLESMORE FROM AUTHOR Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study
